RxDoctor Payments Data

Charles Koh

Milwaukee, WINPI 1770683062

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $13,884,550 of the $13,884,646 with a category attached, or 100.0%. Coopersurgical, Inc. accounts for 98.8% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $3,483,596 and has fallen 75.8% since, to $843,031 in 2025.

$13,884,646in general payments, 2019–2025

Across 38 payments — averaging $365,385 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopersurgical, Inc.$13.7M
  • KARL Storz Endoscopy-america$151K
  • KARL Storz SE & Co. KG$9K

What the payments were for

  • Royalty or licence$13,884,550100%
  • Food & beverage$960%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Coopersurgical, Inc.31$13,724,286
KARL Storz Endoscopy-america6$151,433
KARL Storz SE & Co. KG1$8,927

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →